Analyst consensus rating
Kazia Therapeutics Analyst Rating: Strong Buy
Direct answer
Kazia Therapeutics's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.80.
Forecast evidence checked September 18, 2026.
Get free Kazia Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.42
- Average price target
- $28.80
- High price target
- $39.46
- Low price target
- $17.82
- Low target gap
- +71.1%
- Target upside
- +176.5%
- High target gap
- +278.9%
- Target range width
- 207.8%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- September 18, 2026
- Valid through
- September 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kazia Therapeutics?
Kazia Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $28.80.
How far are Kazia Therapeutics's low and high targets from the recorded price?
The low target implies +71.1%, while the high target implies +278.9%.
How many analysts are included in Kazia Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Kazia Therapeutics's target upside or downside calculated?
The average target of $28.80 is divided by the recorded price of $10.42, then one is subtracted to produce +176.5%. This does not guarantee a future return.
When was Kazia Therapeutics's analyst forecast verified?
The data was verified on 2026-09-18. The dataset is valid through 2026-09-25.